Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.
This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.
Measures of frailty and comorbidity failed to offer predictive information regarding complications in patients with bladder cancer undergoing radical cystectomy.
New research in Lancet Oncology confirms previous studies in this population on the addition of apalutamide to androgen deprivation therapy.
A study in Cancer found a lower risk of prostate cancer–specific death and improved overall survival when patients were treated with this combination.
A study shows T1a RCC patients have improved overall survival when receiving partial nephrectomy compared with radical nephrectomy.
A radiographic measure may help clinicians distinguish between benign renal oncocytoma and chromophobe renal cell carcinoma.
New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.
By elevating the expression of ANO7, a potential prostate cancer susceptibility gene, it may be possible to predict disease severity and outcome.
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.